MINIEYE is most likely a pullback scheme.

The afternoon session will be moved forward to 14:15-16:15 tomorrow.

Let's talk about the three stocks that ended subscription today: iFlytek Healthcare Technology, Innoscience, and Health Path.

When I wrote the article last night, I was pretty sure Health Path wouldn't exceed 15 times oversubscription. But when I woke up this morning, it had already exceeded 15 times on the surface, not to mention the uncalculated bank margin data.

Exceeding 15 times definitely lowers the value-to-bet ratio.

Honestly, these three stocks are all garbage. In the past, I wouldn't even bother writing an analysis—just skip the subscription.

But people keep asking, and there's my own circle, so I have to pick the least rotten one out of three bad apples—Health Path.

And yet, it still exceeded 15 times this morning. All I can hope for now is a trickle-down allocation.

Also, I got some insider info from my friend in the institutional placement team this morning: iFlytek Healthcare Technology might have some tricks up its sleeve post-listing.

Can't reveal too many details, but some institutional placement team leaders hinted they'd give iFlytek Healthcare Technology an "off-market" boost after listing.

Of course, these agreements are just speculation. I only found out this morning, or I might have taken a speculative bet.

The Hong Kong IPO market is full of tricks—both public and private ones.

Retail investors have no say; they can only follow the institutions for scraps.

Except for the big-name stocks, 90% of the price movements of other stocks have nothing to do with their fundamentals.

90% of the small and mid-cap stocks listed in Hong Kong are garbage, yet people still obsess over fundamental analysis for subscriptions.